MAGEB2 binding constructs

US12312412B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• AMGEN RESEARCH (MUNICH) GMBH · DE
• Immatics Biotechnologies GmbH · DE

Inventors

• Ian Foltz · Burnaby, CA
• Weihsu Claire Chen · Toronto, CA
• Lars Gaedtke · Munich, DE
• Susmith Mukund · Foster City, US
• Tobias Raum · Munich, DE
• Heiko SCHUSTER · Rötteln, DE
• Kristin Tarbell · Millbrae, US
• Derek E. Piper · Santa Clara, US
• Johannes Brozy · Munich, DE
• Markus Muenz · Lenggries, DE
• Igor D'ANGELO · Lodi, US
• Alexander Sternjak · Munich, DE

Key dates

• Filing date: May 18, 2021
• Grant date: May 27, 2025
• Expiry date: May 18, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.